Allogeneic Cell Therapy

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY), to develop and commercialize allogeneic cell therapies for oncology indications. The collaboration includes...

Shares Pluristem Therapeutics Inc. (NASDAQ: PSTI), a biotherapeutics company that develops off-the-shelf allogeneic cell therapy products, surged higher by more than 16 percent on Thursday. Pluristem Therapeutics announced on Thursday that the U.S. Food and Drug Administration (FDA) granted the...